To that end, in collaboration with the University of Zurich and MD Anderson Cancer Center, the researchers tested
melanoma tumor samples from human patients undergoing treatment with the same targeted therapies.
Not exact matches
The Ogretmen laboratory screened previously reported microarray data sets of several human
tumor tissues (metastatic head and neck squamous cell carcinoma,
melanoma, and renal cell carcinoma) and showed that, in these
samples, only the levels of CerS4 were significantly decreased.
The research team analyzed BRAF inhibitor resistance in
melanoma cell lines, mice bearing human
melanoma tumors, and in human
tumor biopsy
samples.
Unlike other solid
tumors, there has been limited progress in understanding the contribution of genetic risk factors to the development of uveal
melanoma, researchers say, primarily due to the absence of comprehensive genetic data from patients as the large
sample cohorts for this rare cancer type have not been available for research.
In close collaboration with oncologists at the Olivia Newton John Cancer Research Institute (ONJCRI), the technology was tested on blood
samples from
melanoma patients and was able to track critical changes in spreading
tumor cells before, during and after treatment.
The researchers used
tumor tissue
samples from
melanoma patients to search for variations in their internal messaging.